Abstract
Background: A subset of asthmatics shows refractoriness to Salbutamol owing to ADRB2 gene CT polymorphism (rs 1800888) that substitutes Thr to Ile at the position 164 in the β2 adrenergic receptor leading to sub-optimal binding of Salbutamol. The present study aims to associate the Salbutamol (200 mcg) refractoriness with the polymorphism and select the best existing agonist with optimal binding affinity against wild and mutated receptor and further identify high affinity compound, irrespectively targeting wild and mutated receptor through virtual screening methods. Methods: Responders to Salbutamol were categorized, if percentage reversibility was greater than or equal to 12% in them, while those showing reversibility less than 12% were non-responders. The genotyping for polymorphism was performed by ARMS PCR method. Established agonists with consistent binding affinity against wild and mutated receptors formed query compound to identify high affinity molecule from Phase database through 7 point pharmacophore based screening. Results: Polymorphism was significantly associated with non-responders (p= < 0.05) demonstrating it as a major factor of Salbutamol refractoriness. Results from Glide Docking showed that Fenoterol had highest affinity for mutated receptor and stood as second best (after Salbutamol) high affinity agonist for wild receptor among the established β2 agonists. Therefore Fenoterol formed a query molecule (7 point pharmacophore) in identification of high affinity compound for virtual screening process. Conclusion: Compound CACPD2011a-0001278239 identified through virtual screening against 4 million compounds in phase database was shown to irrespectively target both wild and mutated β2 adrenergic receptor with high and consistent affinity which was par greater than established β2agonists.
Keywords: ADRB2 polymorphism, β2AR receptor mutation, salbutamol, fenoterol, 7 point pharmacophore modeling, virtual screening.
Current Pharmaceutical Design
Title:Identification of Small Molecule as a High Affinity β2 Agonist Promiscuously Targeting Wild and Mutated (Thr164Ile) β 2 Adrenergic Receptor in the Treatment of Bronchial Asthma
Volume: 22 Issue: 34
Author(s): Srinivas Bandaru, Mallika Alvala, Jyothy Akka, Someshwar Rao Sagurthi, Anuraj Nayarisseri, Sanjeev Kumar Singh and Hema Prasad Mundluru
Affiliation:
Keywords: ADRB2 polymorphism, β2AR receptor mutation, salbutamol, fenoterol, 7 point pharmacophore modeling, virtual screening.
Abstract: Background: A subset of asthmatics shows refractoriness to Salbutamol owing to ADRB2 gene CT polymorphism (rs 1800888) that substitutes Thr to Ile at the position 164 in the β2 adrenergic receptor leading to sub-optimal binding of Salbutamol. The present study aims to associate the Salbutamol (200 mcg) refractoriness with the polymorphism and select the best existing agonist with optimal binding affinity against wild and mutated receptor and further identify high affinity compound, irrespectively targeting wild and mutated receptor through virtual screening methods. Methods: Responders to Salbutamol were categorized, if percentage reversibility was greater than or equal to 12% in them, while those showing reversibility less than 12% were non-responders. The genotyping for polymorphism was performed by ARMS PCR method. Established agonists with consistent binding affinity against wild and mutated receptors formed query compound to identify high affinity molecule from Phase database through 7 point pharmacophore based screening. Results: Polymorphism was significantly associated with non-responders (p= < 0.05) demonstrating it as a major factor of Salbutamol refractoriness. Results from Glide Docking showed that Fenoterol had highest affinity for mutated receptor and stood as second best (after Salbutamol) high affinity agonist for wild receptor among the established β2 agonists. Therefore Fenoterol formed a query molecule (7 point pharmacophore) in identification of high affinity compound for virtual screening process. Conclusion: Compound CACPD2011a-0001278239 identified through virtual screening against 4 million compounds in phase database was shown to irrespectively target both wild and mutated β2 adrenergic receptor with high and consistent affinity which was par greater than established β2agonists.
Export Options
About this article
Cite this article as:
Bandaru Srinivas, Alvala Mallika, Akka Jyothy, Sagurthi Rao Someshwar, Nayarisseri Anuraj, Singh Kumar Sanjeev and Mundluru Prasad Hema, Identification of Small Molecule as a High Affinity β2 Agonist Promiscuously Targeting Wild and Mutated (Thr164Ile) β 2 Adrenergic Receptor in the Treatment of Bronchial Asthma, Current Pharmaceutical Design 2016; 22 (34) . https://dx.doi.org/10.2174/1381612822666160513145721
DOI https://dx.doi.org/10.2174/1381612822666160513145721 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Controversies in Glaucoma: Current Medical Treatment and Drug Development
Current Pharmaceutical Design TNF-Alpha Antagonism in Severe Asthma?
Recent Patents on Inflammation & Allergy Drug Discovery Drug Discovery in Enteroviral Infections
Infectious Disorders - Drug Targets TRPM8 Biology and Medicinal Chemistry
Current Topics in Medicinal Chemistry Granulomatous Lung Disease. Disease for Pulmomologists: Diagnosis and Treatment
Current Respiratory Medicine Reviews Global View on Rare Diseases: A Mini Review
Current Medicinal Chemistry Evaluating the Effect of Cinnarizine on Promastigotes and Amastigotes forms of Leishmania major
Infectious Disorders - Drug Targets Optimized Turmeric Extracts have Potent Anti-Amyloidogenic Effects
Current Alzheimer Research Modulation of the Fce Receptor I Signaling by Tyrosine Kinase Inhibitors: Search for Therapeutic Targets of Inflammatory and Allergy Diseases
Current Pharmaceutical Design Aerosol Devices and Asthma Therapy
Current Drug Delivery Neuromodulatory and Anti-Inflammatory Ingredient for Sensitive Skin: In Vitro Assessment
Inflammation & Allergy - Drug Targets (Discontinued) Early-Life Immune Insult and Developmental Immunotoxicity (DIT)-Associated Diseases: Potential of Herbal- and Fungal-Derived Medicinals
Current Medicinal Chemistry The Yin and Yang of Inflammation
Current Molecular Medicine Changes in Serum Amino Acids in Migraine Patients without and with Aura and their Possible Usefulness in the Study of Migraine Pathogenesis
CNS & Neurological Disorders - Drug Targets Chemoprotective Mechanism of the Natural Compounds, Epigallocatechin- 3-O-Gallate, Quercetin and Curcumin Against Cancer and Cardiovascular Diseases
Current Medicinal Chemistry Advances in Exploring the Role of Micrornas in Inflammatory Bowel Disease
MicroRNA Immunopathological Aspects of Mycoplasma pneumoniae Infection
Current Pediatric Reviews PPARγ: Potential Therapeutic Target for Ailments Beyond Diabetes and its Natural Agonism
Current Drug Targets Therapeutic Management of Atopic Eczema
Current Drug Metabolism Lymphatic Targeting of Nanosystems for Anticancer Drug Therapy
Current Pharmaceutical Design